Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IN10018 and PLD in Platinum-Resistant High-Grade Serous Ovarian Cancer
NCT05551507Phase 2Recruiting
- Sponsor
- InxMed
- Start
- Jul 2020
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ifebemtinib in ovarian cancer, sponsored by InxMed. Started Jul 2020; status: recruiting.
02
Drugs
ifebemtinib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT05551507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05551507.